NEW ORIGINAL ANTIHISTAMINE BILASTINE IN THE TREATMENT OF ALLERGIC RHINITIS
https://doi.org/10.21518/2079-701X-2017-16-88-90
Abstract
Allergic rhinitis is one of most widespread human diseases associated with severe limitations in physical, psychological, and social aspects of life, which is the reason for the decline in quality of life. The drugs of first choice in patients with symptoms of seasonal and perennial allergic rhinitis of intermittent as well as of persistent courses are antihistamines of 2nd generation with high affinity to H1-receptors. The article is about a new representative of the above group of drugs, the original drug Niksar® (bilastine).
About the Authors
A. A. Krivopalov
Saint-Petersburg Scientific and Research Institute of Ear, Throat, Nose and Speech of the Ministry of Health of RF
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
O. I. Konoplev
Saint-Petersburg Scientific and Research Institute of Ear, Throat, Nose and Speech of the Ministry of Health of RF
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
S. V. Shervashidze
Saint-Petersburg Scientific and Research Institute of Ear, Throat, Nose and Speech of the Ministry of Health of RF
Russian Federation
Russian Federation
V. A. Shatalov
Saint-Petersburg Scientific and Research Institute of Ear, Throat, Nose and Speech of the Ministry of Health of RF
Russian Federation
Russian Federation
References
1. Lucero ML, Gonzalo A, Mumford R, Betanzos M, Alejandro A. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol, 2012, 35(suppl l): 18-24.
2. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen. Allergy, 2008, 63(Suppl. 86): 8-160.
3. Василевский И.В. Реабилитация детей и подростков с заболеваниями органов дыхания, пищеварения, почек, сердечно-сосудистой системы и аллергическими болезнями в условиях поликлиники. Минск: БелМАПО, 2007: 157-171.
4. Горячкина Л.А., Кашкин Е.П., Терехова Е.П. и соавт. Клиническая аллергология и иммунология: руководство для практикующих врачей. Под ред. Л.А. Горячкиной и Е.П. Кашкина. М.: Миклош, 2009: 121.
5. Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B. Effects ofbilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig, 2012, 32: 339-351.
6. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol, 1988, 94:187-191.
7. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol, 1940, 30:121-145.
8. Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol, 1960, 151:416-435.
9. Sadaba B, Gomez-Guiu A, Azanza JR, Ortega I, Valiente R. Oral availability of bilastine. Clin Drug Investig, 2013, 33: 375-381.
10. Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy, 2013, 68: 921-928.
11. Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf, 2011, 10(5): 779-793.
12. Corcostegui R, Labeaga L, Innerarity A, Berisa A, Oijales A. In vivo pharmacological characterisation of bilastine, a potent and selective histamine HI receptor antagonist. Drugs R D, 2006,7: 219-231.
13. Sastre J, Mullol J, Valero A, Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin, 2012, 28: 121-130.
14. Zuberbier T, Oanta A, Bogacka E. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vslevocetirizine 5 mg forthe treatment of chronic idiopathic urticaria: a multi-centre, doubleblind, randomized, placebo-controlled study. Allergy, 2010, 65: 516-528.
15. Prepageran N, Wangde Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic lhinosinusitis: a Malaysian perspective. Asia Рас Allergy, 2014, 4: 142-148.
16. Tashiro M, Sakurada Y, Iwabuchi K et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamineHI-receptor occupancy using 1 lC-doxepin positron emission tomography. JClinPharmacol,2004, 44: 890-900.
Review
For citations:
Krivopalov AA, Konoplev OI, Shervashidze SV, Shatalov VA. NEW ORIGINAL ANTIHISTAMINE BILASTINE IN THE TREATMENT OF ALLERGIC RHINITIS. Meditsinskiy sovet = Medical Council. 2017;(16):88-90. (In Russ.) https://doi.org/10.21518/2079-701X-2017-16-88-90
Views:
2360
Email this article 